

Ciclosporin

We recommend using ciclosporin to achieve disease control in AE patients who are candidates for systemic treatment.	↑↑	>75% Evidence and consensus based, see Evidence Report
--	----	---

ciclosporin: in licence for ≥ 16 years of age
 standard dosage adults: 2.5-5 mg/kg per day in two single doses
 commonly used dosage children: 2.5-5 mg/kg per day in two single doses

Certainty of evidence: Network meta-analysis from 2022^{1, 2}:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice or likely to be approved soon)

Higher dose

⊕⊕⊕○ MODERATE for standardized mean difference **change in signs** -1 (-1.6, -0.4)
 ⊕⊕⊕○ MODERATE for standardized mean difference **QoL** -0.7 (-1.3, -0.1)
 ⊕⊕○○ LOW for standardized mean difference itch -0.7 (-1.5, 0.2)

Lower dose

⊕⊕⊕○ MODERATE for standardized mean difference **change in signs** -0.7 (-1.4, -0.1)
 ⊕⊕○○ LOW for standardized mean difference QoL -0.5 (-1.1, 0.2)
 ⊕⊕○○ LOW for standardized mean difference itch -0.7 (-1.6, 0.3)

For ciclosporin versus other drugs, see Evidence Report

We recommend to start with higher ciclosporin dosages in order to achieve a more rapid response in AE patients who are candidates for systemic treatment.	↑↑	100% Expert Consensus
--	----	---------------------------------

We recommend close follow-up for potential blood pressure elevation and signs of renal impairment in AE patients on ciclosporin.	↑↑	100% Expert Consensus
---	----	---------------------------------

Mechanisms of action and efficacy

Ciclosporin inhibits T cell activation and proliferation by blocking nuclear factor of activated T cells (NFAT)-dependent cytokine production.

Ciclosporin has been approved for treatment of AE in adults in many European countries and is considered as first line option for patients with severe disease if other, novel therapies are not available or indicated. Ciclosporin is very effective for AE in both children and adults with a better tolerability in children.³⁻⁵ Although similarly effective in the above NMA meta-analysis evaluating adult trials up to 16 weeks and in a real world analysis from the UK-Irish Atopic Eczema Systemic TherApy Register (A-STAR) among both adults and children⁶, real life data reveal a longer drug survival of dupilumab

compared to ciclosporin after 16 months, but similar effectiveness.^{7, 8} In head-to-head adult trials ciclosporin was superior to MTX, prednisolone, IVIG, UVA and UVB, and similarly efficacious as enteric-coated mycophenolate sodium (EC-MPS).^{9, 10}

In an investigator-blinded randomised controlled trial comparing ciclosporin (4 mg/kg/day) with MTX (0.4 mg/kg/week) in children aged 2 to 16 years (n=103), participants receiving ciclosporin showed a faster response to treatment by 12 weeks (TREAT trial). However, MTX was superior after this time point, with more sustained disease control seen up to week 60, even after treatment was stopped at 36 weeks (lower disease severity measured by EASI and o-SCORAD as well as less patient-reported flares and reduced need for the use of topical anti-inflammatory treatment), suggesting potential disease modification through MTX.¹¹ Both drugs improved QoL above the minimal important difference for the CDLQI and were adequately tolerated and there were no serious adverse events attributed to either medication. In addition, there was no significant impact on either treatment on renal tubular function, using sensitive tubular biomarkers.¹¹ In the short-term treatment of AE, higher ciclosporin dosages (5 mg/kg per day) lead to a more rapid response and are more efficacious than lower dosages (2.5-3 mg/kg per day).⁹ Longterm use of ciclosporin up to 1 year is possible, however, supporting evidence is limited.⁹

Dosage: acute flare, short term, long term

- licensed \geq 16 years of age
- standard dosage adults: 2.5-5 mg/kg per day in two single doses
 - Acute flare, short-term: 4-5 mg/kg body weight per day
 - Long-term: 2.5-3 mg/kg body weight per day
- commonly used dosage children: 2.5-5 mg/kg per day in two single doses
- We recommend combining ciclosporin, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.

Safety

Ciclosporin has a narrow therapeutic index and requires a close follow-up for blood pressure and signs of renal impairment. To note, clinically relevant increase of creatinine seems less common than expected, as recently confirmed in the TREAT trial, which showed no abnormal renal profiles due to ciclosporin, even when sensitive tubular function biomarkers were used (see above).^{4, 11, 12} Oral hygiene is important to prevent gingival hyperplasia.

Screening and monitoring

- Screening for hepatitis B/C and HIV before therapy should be considered (see also section 8.1 Introduction conventional immunomodulatory drugs)
- Screening and follow up monitoring: Blood pressure, full blood count, renal and liver profile (including GGT) according to national guidelines (e.g. at baseline, 4 weeks and then 3-monthly).

Combination with other treatments

We recommend combining ciclosporine, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. Because of a potentially increased risk to develop skin cancer, ciclosporin should not be combined with UV light (UVA, UVB, PUVA).

Special considerations

Ciclosporin has been shown to be effective in and is better tolerated by children and adolescents.^{3, 5, 13}

Ciclosporin can be considered in pregnant woman with severe AE. So far, no increased risk of congenital malformations or fetal death compared to the background populations have been reported. An increased risk of low birthweight cannot be ruled out.¹⁴ Where systemic therapy is likely to be needed throughout pregnancy, ciclosporin is first choice therapy.¹⁴

Ciclosporin is an inhibitor of CYP3A4, the multidrug efflux transporter P-glycoprotein (P-gp), and the organic anion transporters (OATP). Concurrent use of drugs that are substrates of CYP3A4, P-gp, and OATP with ciclosporin can therefore lead to increased plasma concentrations of these co-administered drugs, which are substrates of these enzymes and/or transporters

References

1. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochweg B et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. *JAMA Dermatol* 2022;158(5):523–32.
2. Drucker AM. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 2022. Available at: <https://eczematherapies.com/research/> (last accessed 12 May 2025).
3. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2007;21(5):606–19.
4. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. *J Am Acad Dermatol* 2019;80(2):411–6.e4.
5. Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. *Br J Dermatol* 2023;189(6):674–84.
6. Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. *Br J Dermatol* 2024;
7. Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochweg B et al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. *JAMA Dermatol* 2020;156(6):659–67.
8. Dal Bello G, Maurelli M, Schena D, Girolomoni G, Gisondi P. Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients. *Dermatol Ther* 2020;33(6):e13979.
9. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. *J Allergy Clin Immunol* 2014;133(2):429–38.
10. Goujon C, Viguier M, Staumont-Sallé D, Bernier C, Guillet G, Lahfa M et al. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. *J Allergy Clin Immunol Pract* 2018;6(2):562–9.e3.
11. Bruce G, Rosala-Hallas A, Jones AP, Turner C, Dalton N, Hilger E et al. The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children - results from the TREAT trial. *Br J Dermatol* 2024;
12. van der Schaft J, van Zuilen AD, Deinum J, Bruijnzeel-Koomen CA, de Bruin-Weller MS. Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis. *Acta Derm Venereol* 2015;95(8):963–7.
13. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. *J Am Acad Dermatol* 1996;34(6):1016–21.
14. Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol* 2019;33(9):1644–59.